PMV Pharmaceuticals, Inc. (PMVP)

Market Cap	222.46M
Revenue (ttm)	n/a
Net Income (ttm)	-73.32M
Shares Out	45.77M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	528,262
Open	5.02
Previous Close	5.05
Day's Range	4.84 - 5.10
52-Week Range	4.84 - 24.27
Beta	0.99
Analysts	Buy
Price Target	22.27 (+358.23%)
Earnings Date	May 9, 2023

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and change...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: PMVP

Analyst Forecast

According to 13 analysts, the average rating for PMVP stock is "Buy." The 12-month stock price forecast is $22.27, which is an increase of 358.23% from the latest price.

Price Target

$22.27

(358.23% upside)

Analyst Consensus: Buy